RU2643811C2 - Способ получения гидроксилированных циклопентилпиримидиновых соединений - Google Patents

Способ получения гидроксилированных циклопентилпиримидиновых соединений Download PDF

Info

Publication number
RU2643811C2
RU2643811C2 RU2014151050A RU2014151050A RU2643811C2 RU 2643811 C2 RU2643811 C2 RU 2643811C2 RU 2014151050 A RU2014151050 A RU 2014151050A RU 2014151050 A RU2014151050 A RU 2014151050A RU 2643811 C2 RU2643811 C2 RU 2643811C2
Authority
RU
Russia
Prior art keywords
compound
formula
salt
alkyl
substituted
Prior art date
Application number
RU2014151050A
Other languages
English (en)
Russian (ru)
Other versions
RU2014151050A (ru
Inventor
Дэвид Аскин
Чун ХАНЬ
Джонатан В. ЛЭЙН
Трэвис РЕМАРЧУК
Сагар ШАКЬЯ
К. Грегори Сауэлл
Кейт Л. Спенсер
Питер Дж. СТЕНДЖЕЛ
Original Assignee
Аррэй Байофарма Инк.
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аррэй Байофарма Инк., Дженентек, Инк. filed Critical Аррэй Байофарма Инк.
Publication of RU2014151050A publication Critical patent/RU2014151050A/ru
Application granted granted Critical
Publication of RU2643811C2 publication Critical patent/RU2643811C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
RU2014151050A 2012-05-17 2013-05-17 Способ получения гидроксилированных циклопентилпиримидиновых соединений RU2643811C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US61/648,473 2012-05-17
US201361785122P 2013-03-14 2013-03-14
US61/785,122 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
RU2014151050A RU2014151050A (ru) 2016-07-10
RU2643811C2 true RU2643811C2 (ru) 2018-02-06

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014151050A RU2643811C2 (ru) 2012-05-17 2013-05-17 Способ получения гидроксилированных циклопентилпиримидиновых соединений

Country Status (20)

Country Link
US (4) US9416110B2 (enExample)
EP (1) EP2861582B1 (enExample)
JP (1) JP6284928B2 (enExample)
KR (1) KR102067850B1 (enExample)
CN (1) CN104470913B (enExample)
AU (1) AU2013262505B2 (enExample)
BR (1) BR112014028589B1 (enExample)
CA (1) CA2873654C (enExample)
DK (1) DK2861582T3 (enExample)
ES (1) ES2582557T3 (enExample)
IL (1) IL235715A (enExample)
MX (1) MX353384B (enExample)
MY (1) MY169028A (enExample)
NZ (1) NZ702935A (enExample)
PL (1) PL2861582T3 (enExample)
RU (1) RU2643811C2 (enExample)
SG (1) SG11201407616TA (enExample)
SI (1) SI2861582T1 (enExample)
WO (1) WO2013173768A1 (enExample)
ZA (1) ZA201409261B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712224C2 (ru) * 2014-09-26 2020-01-27 Ф. Хоффманн-Ля Рош Аг Способы получения (циклопентил[d]пиримидин-4-ил)пиперазиновых соединений

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CN112898210B (zh) 2013-11-15 2025-02-21 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
CN120887837A (zh) 2020-06-16 2025-11-04 豪夫迈·罗氏有限公司 用于制备羟基化环戊基嘧啶化合物的方法
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188754A1 (en) * 1999-06-03 2002-03-20 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US20080051399A1 (en) * 2006-07-06 2008-02-28 Mitchell Ian S Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2011050016A1 (en) * 2009-10-23 2011-04-28 Eli Lilly And Company Akt inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188754A1 (en) * 1999-06-03 2002-03-20 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US20080051399A1 (en) * 2006-07-06 2008-02-28 Mitchell Ian S Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
RU2478632C2 (ru) * 2006-07-06 2013-04-10 Эррэй Биофарма Инк. Гидроксилированные и метоксилированные циклопента[d]пиримидины в качестве ингибиторов акт протеинкиназ
WO2011050016A1 (en) * 2009-10-23 2011-04-28 Eli Lilly And Company Akt inhibitors
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712224C2 (ru) * 2014-09-26 2020-01-27 Ф. Хоффманн-Ля Рош Аг Способы получения (циклопентил[d]пиримидин-4-ил)пиперазиновых соединений

Also Published As

Publication number Publication date
EP2861582A1 (en) 2015-04-22
JP6284928B2 (ja) 2018-02-28
CN104470913A (zh) 2015-03-25
JP2015517532A (ja) 2015-06-22
ES2582557T3 (es) 2016-09-13
US20160318877A1 (en) 2016-11-03
HK1208451A1 (en) 2016-03-04
US20180258054A1 (en) 2018-09-13
IL235715A (en) 2017-02-28
KR102067850B1 (ko) 2020-01-17
CA2873654A1 (en) 2013-11-21
NZ702935A (en) 2017-02-24
MY169028A (en) 2019-02-04
US20170247337A1 (en) 2017-08-31
US9790190B2 (en) 2017-10-17
MX2014013862A (es) 2015-05-07
MX353384B (es) 2018-01-10
ZA201409261B (en) 2017-05-31
EP2861582B1 (en) 2016-05-25
PL2861582T3 (pl) 2016-11-30
BR112014028589B1 (pt) 2022-08-23
CA2873654C (en) 2021-06-22
US9416110B2 (en) 2016-08-16
US9676730B2 (en) 2017-06-13
RU2014151050A (ru) 2016-07-10
DK2861582T3 (en) 2016-08-22
CN104470913B (zh) 2018-07-20
AU2013262505A1 (en) 2015-01-22
IL235715A0 (en) 2015-02-01
KR20150020214A (ko) 2015-02-25
US20150152067A1 (en) 2015-06-04
WO2013173768A1 (en) 2013-11-21
BR112014028589A2 (pt) 2017-07-25
AU2013262505B2 (en) 2017-09-21
SI2861582T1 (sl) 2016-09-30
SG11201407616TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
KR102067850B1 (ko) 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법
AU2019253849A1 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
US20240158371A1 (en) Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
BR112014028585B1 (pt) processo para fabricação de aminoácidos, e seus intermediários
EP4622972A1 (en) Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound
HK1208451B (en) Process for making hydroxylated cyclopentylpyrimidine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
JP4328852B2 (ja) Tan−1251合成中間体
NZ731073B2 (en) PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS